Sorbent Therapeutics, Inc., is a private biopharmaceutical company focused on the development of oral, non-absorbed polymeric drugs to satisfy unmet needs in large cardio-renal markets, such as heart failure, chronic kidney disease and hypertension.
The array of customized compounds under development in our pipeline is based on Sorbent's proprietary, robust cross-linked polyelectrolyte (CLP) polymer technology. The CLP products are designed to manage serious, chronic conditions while passing through the GI tract unabsorbed, thus minimizing systemic exposure and potential side effects
